CN105334243A - Blood analyzer - Google Patents
Blood analyzer Download PDFInfo
- Publication number
- CN105334243A CN105334243A CN201410318293.8A CN201410318293A CN105334243A CN 105334243 A CN105334243 A CN 105334243A CN 201410318293 A CN201410318293 A CN 201410318293A CN 105334243 A CN105334243 A CN 105334243A
- Authority
- CN
- China
- Prior art keywords
- measurement
- module
- crp
- blood
- hematocrit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 176
- 239000008280 blood Substances 0.000 title claims abstract description 176
- 238000005259 measurement Methods 0.000 claims abstract description 220
- 238000005534 hematocrit Methods 0.000 claims abstract description 124
- 238000011546 CRP measurement Methods 0.000 claims abstract description 41
- 238000012937 correction Methods 0.000 claims abstract description 34
- 239000003219 hemolytic agent Substances 0.000 claims abstract description 15
- 238000001514 detection method Methods 0.000 claims description 76
- 210000000601 blood cell Anatomy 0.000 claims description 59
- 210000002966 serum Anatomy 0.000 claims description 23
- 210000000265 leukocyte Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000012895 dilution Substances 0.000 claims description 17
- 238000010790 dilution Methods 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 15
- 238000004820 blood count Methods 0.000 claims description 9
- 210000003743 erythrocyte Anatomy 0.000 claims description 7
- 238000002847 impedance measurement Methods 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 5
- 108010054147 Hemoglobins Proteins 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 210000003651 basophil Anatomy 0.000 claims description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 123
- 102100032752 C-reactive protein Human genes 0.000 description 123
- 239000000523 sample Substances 0.000 description 20
- 238000010586 diagram Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to a blood analyzer, including a mode selection unit, a measuring unit and a control unit. The mode selection unit is for selecting a measurement mode from a measurement mode set; and the measurement mode set comprises at least a whole blood CRP individual measurement mode. The control unit calls the corresponding module in the measurement unit for measurement according to the measurement mode selected by the mode selection unit. The measuring unit at least includes a hematocrit measurement module, a whole blood CRP measurement module and a correction module; the correction module corrects the whole blood CRP concentration obtained by the whole blood CRP measurement module according to the hematocrit value obtained by the hematocrit measurement module, so as to obtain corrected CRP concentration value. The blood analyzer can individually measure the whole blood CRP concentration values, only needs a small amount of blood to realize CRP concentration measurements and reduces the use amount of a hemolytic agent. The blood analyzer has the advantages of low cost, simple operation, and good application prospects, and can be used for clinical popularization and application.
Description
Technical Field
The invention relates to the field of medical equipment, in particular to a blood analyzer.
Background
The C-reactive protein (CRP) is an acute phase protein synthesized by liver cells when an organism is subjected to inflammatory stimulation such as microbial invasion or tissue injury, the CRP is increased within hours after inflammation begins, the peak value can be reached within 48 hours, and along with regression of lesions and recovery of tissues, structures and functions, the CRP is reduced to a normal level.
One of the current methods for measuring the concentration value of CRP in the industry is to measure the concentration value of CRP in serum, and japanese patent No.11575/1983 discloses an immunoassay method which utilizes the characteristic that an antigen or an antibody on an insoluble substance is combined with a corresponding antibody or antigen on a sample to form an agglutinate, irradiates the agglutinate with a light wave having a wavelength of 600nm to 2400nm, and finally obtains the parameter of the antigen by analyzing the degree of absorption (absorbance) or scattering (scattered) of the light. However, when this method is used to perform CRP testing on serum, serum needs to be extracted from whole blood, and the blood sample required for testing is relatively large.
Another method for measuring CRP concentration values is to use whole blood, but when the existing hematology analyzer uses whole blood to measure CRP, the conventional blood measurement is performed at the same time, so that the required blood sample to be tested is relatively large.
In summary, the existing CRP detecting devices require relatively large blood samples, and the measurement of CRP concentration values is difficult for patients with difficult blood sampling, especially pediatric patients, with small blood volume.
Disclosure of Invention
Therefore, the invention provides a blood analyzer which has less blood volume and accurate detection result and can independently detect the CRP concentration value, aiming at the problem that the conventional CRP detection device has larger required blood sample volume.
In order to solve the technical problems, the technical scheme of the invention is as follows:
a blood analyzer, comprising:
a mode selection unit, which is used for selecting a measurement mode from a measurement mode set, wherein the measurement mode set at least comprises a whole blood CRP single measurement mode;
the measuring unit at least comprises a hematocrit measuring module, a whole blood CRP measuring module and a correcting module; the correction module corrects the whole blood CRP concentration value obtained by the whole blood CRP measurement module according to the hematocrit value obtained by the hematocrit measurement module to obtain a corrected CRP concentration value;
and the control unit calls the hematocrit measuring module, the whole blood CRP measuring module and the correction module to measure the CRP concentration value when the whole blood CRP single measuring mode is selected by the mode selection unit.
Preferably, the measurement pattern set further includes one or more of a CBC blood cell classification and CRP pattern, a CBC blood cell classification measurement pattern, a CBC measurement, and a CRP pattern.
Preferably, the measurement unit further comprises: the device comprises a BASO detection module, a DIFF detection module and an HGB detection module; the BASO detection module is used for detecting white blood cell counting and basophil granulocyte classification, the DIFF detection module is used for detecting four types of white blood cells, and the HGB detection module is used for detecting hemoglobin concentration.
Preferably, the measurement unit further comprises: a leukocyte counting module, a three-classification module and an HGB detection module.
Preferably, the control unit further comprises:
when the mode selection unit selects the CBC blood cell classification measurement mode, calling the BASO detection module, the DIFF detection module, the HGB detection module and the hematocrit measurement module to carry out five classification measurement on the CBC blood cells;
when the CBC blood cell classification and CRP mode is selected by the mode selection unit, calling the BASO detection module, the DIFF detection module, the HGB detection module and the hematocrit measurement module to perform five-classification measurement on the CBC blood cells, and calling the hematocrit measurement module, the whole blood CRP measurement module and the correction module to perform CRP concentration value measurement;
when the CBC measurement and the CRP mode are selected by the mode selection unit, the BASO detection module, the HGB detection module and the hematocrit measurement module are called to carry out the CBC measurement, and the hematocrit measurement module, the whole blood CRP measurement module and the correction module are called to carry out the CRP concentration value measurement.
Preferably, the control unit further comprises:
when the mode selection unit selects the CBC blood cell classification measurement mode, calling the white blood cell counting and three classification modules thereof, the HGB detection module and the hematocrit measurement module to carry out three classification measurements of the CBC blood cells;
and when the CBC blood cell classification and CRP mode is selected by the mode selection unit, calling the white blood cell counting and three classification modules thereof, the HGB detection module and the hematocrit measurement module to carry out three-classification measurement on the CBC blood cells, and calling the hematocrit measurement module, the whole blood CRP measurement module and the correction module to carry out CRP concentration value measurement.
Preferably, the whole blood CRP measurement module determines the dose of the added hemolytic agent based on the hematocrit value measured by the hematocrit measurement module.
Preferably, the blood analyzer further comprises a test type automatic selection unit, and the measurement unit further comprises a serum CRP measurement module;
the automatic test type selection unit judges whether the measured blood sample is serum or plasma when the hematocrit value measured by the hematocrit measurement module is smaller than a preset threshold value, and calls the serum CRP measurement module to measure the CRP concentration value; otherwise, the measured blood sample is judged to be whole blood, and the whole blood CRP measuring module and the correction module are called to measure the CRP concentration value.
Preferably, the hematocrit measurement module is an impedance measurement module.
Preferably, the impedance measuring module comprises a primary liquid adding dilution submodule, a secondary liquid adding dilution submodule, a blending submodule, an impedance method red blood cell measuring submodule and a hematocrit calculating submodule.
Compared with the prior art, the technical scheme of the invention has the following advantages: the blood analyzer provided by the invention can be used for separately measuring whole blood CRP, can realize CRP concentration value measurement only by a small blood volume, and can reduce the using amount of hemolytic agent. The blood analyzer provided by the invention can complete the measurement of whole blood CRP generally only by 15-25 μ L of blood, while the existing measurement of whole blood CRP concentration value generally requires 30-40 μ L of blood.
Drawings
In order that the present disclosure may be more readily and clearly understood, reference is now made to the following detailed description of the embodiments of the present disclosure taken in conjunction with the accompanying drawings, in which
FIG. 1 is a schematic configuration diagram of a blood analyzer in embodiment 1 of the present invention;
FIG. 2 is a schematic configuration diagram of an impedance measuring module of a blood analyzer in embodiment 1 of the present invention;
FIG. 3 is a flowchart showing the operation of the blood analyzer described in embodiment 1 of the present invention;
FIG. 4 is a schematic configuration diagram of a blood analyzer in embodiment 2 of the present invention;
FIG. 5 is a schematic configuration diagram of a blood analyzer in embodiment 3 of the present invention;
FIG. 6 is a schematic configuration diagram of a blood analyzer in embodiment 4 of the present invention;
fig. 7 is a schematic configuration diagram of a blood analyzer in embodiment 5 of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, embodiments of the present invention will be described in detail with reference to the accompanying drawings.
Example 1
This example provides a hematology analyzer that can measure whole blood CRP concentration values. Since serum CRP concentrations are frequently used in the industry, in order to make whole blood CRP concentration values comparable to serum CRP concentration values, hematocrit information of a whole blood sample is used to correct the whole blood CRP test results. The most common correction methods are;
CRP'＝CRP×100/(100-hematocrit％)
wherein hemotocrit (HCT for short, Hematocrit value) is the Hematocrit value of the whole blood sample, CRP is a CRP concentration value directly obtained by whole blood measurement, and CRP' is a corrected CRP concentration value.
The corrected whole blood CRP concentration values obtained in this way are comparable to the serum CRP concentration values.
The present embodiment provides a blood analyzer, as shown in fig. 1, including a mode selection unit 1, a measurement unit 3, and a control unit 2.
The mode selection unit 1 is configured to select one measurement mode from a measurement mode set, where the measurement mode set includes a whole blood CRP single measurement mode in this embodiment.
The measurement unit 3 comprises a hematocrit measurement module 301, a whole blood CRP measurement module 302, and a correction module 303. The correcting module 303 corrects the whole blood CRP concentration value obtained by the whole blood CRP measuring module 302 according to the hematocrit value measured by the hematocrit measuring module 301 to obtain a corrected CRP concentration value. Here, the specific correction method is as described above and will not be described again.
The control unit 2 calls the hematocrit measuring module 301, the whole blood CRP measuring module 302 and the correcting module 303 in the measuring unit 3 to measure the CRP concentration value when the mode selecting unit 1 selects the whole blood CRP alone measuring mode. Since there is only one whole blood CRP single measurement mode in the mode selection unit 1 in this embodiment, the blood analyzer is used for whole blood CRP single measurement only.
The hematocrit measurement module 301 may be an impedance measurement module, and a structural block diagram of the impedance measurement module is shown in fig. 2, and includes a primary liquid adding dilution sub-module 3011, a secondary liquid adding dilution sub-module 3012, a blending sub-module 3013, an impedance method red blood cell measurement sub-module 3014, and a hematocrit calculation sub-module 3015. Wherein, in the first liquid adding dilution submodule 3011, the amount of the added diluent is 2500ul, and in the second liquid adding dilution submodule 3012, the amount of the added diluent is 1650 ul. The impedance measurement module can increase the total amount of the diluted sample and reduce errors through the process of twice dilution.
The working flow of the blood analyzer in this embodiment is shown in fig. 3, and the process is as follows: after the whole blood CRP measurement mode is determined by a user through the mode selection unit 1, a measured sample is sucked, blood is separated after the sample suction is completed, the blood sample is divided into two parts, one part is used for measuring the hematocrit value through the impedance measurement module, and the other part is used for measuring the CPR concentration value through the whole blood CRP measurement module.
The process of measuring the hematocrit value includes: firstly, diluting by adding a diluent, wherein the dilution is divided into two times of dilution, uniformly mixing the diluted samples after one-time liquid adding dilution and two-time liquid adding dilution, then carrying out erythrocyte measurement by an impedance method, and obtaining a Hematocrit value, namely an HCT value for short, called Hematocrit in English.
The measurement process of the whole blood CRP concentration value comprises the following steps: firstly adding a hemolytic agent, then adding a latex reagent, uniformly mixing, measuring by an immunoturbidimetry method, and then calculating to obtain a CRP concentration value.
Finally, the correcting module 303 corrects the CRP concentration value according to the obtained HCT value to obtain and output a corrected CRP, that is, the measurement of the whole blood CRP concentration value is completed.
The embodiment provides a blood analyzer, which can measure a whole blood CRP concentration value independently, select a measurement mode through the mode selection unit 1, realize the measurement of the whole blood CRP alone, measure a hematocrit value and the whole blood CRP concentration value independently without measuring a blood routine, and obtain a corrected value of the whole blood CRP concentration through a correction method. In the scheme, the blood volume is smaller as the blood routine does not need to be measured and only the hematocrit value is measured independently, the requirement can be met as long as the blood volume is very small, for example, the whole blood CRP can be measured only by 15-25 microliters of blood, and the whole blood CRP is corrected through the hematocrit value, so that the measured value is comparable to the serum CRP concentration value, and the measurement precision is improved. The problems that blood is conventional and the blood demand is large when whole blood CRP is measured in the prior art are solved. The blood analyzer has the advantages of low economic cost, simple operation and good application prospect, and can be clinically popularized and applied.
Example 2
The blood analyzer of the present embodiment has a schematic structural diagram as shown in fig. 4, and has three measurement modes, wherein the measurement mode set includes a whole blood CRP single measurement mode, a CBC blood cell classification and CRP mode, and a CBC blood cell classification measurement mode. The mode selection unit 1 is used for selecting one measurement mode from the measurement mode set composed of the three modes.
CBC is collectively called CompleteBloodCount and refers to whole cell count, and CBC measurement refers to measurement of count and morphological parameters such as WBC (white blood cell), RBC (Redbloodcel red blood cell), PLT (bloodplastet, platelet), HGB (hemoglobin concentration), HCT (hematocrit), and the like. The CBC blood cell classification can be further classified into CBC cell three classification and CBC cell five classification.
In this embodiment, the measurement unit 3 includes a BASO detection module 304, a DIFF detection module 305, an HGB detection module 306, a hematocrit measurement module 301, a whole blood CRP measurement module 302, and a correction module 303. Wherein,
the BASO detection module 304 is for detecting white blood cell count and basophil classification;
the DIFF detection block 305 is used to detect four classes of white blood cells (lymphoid, mononuclear, neutrophilic, eosinophilic);
the HGB detection module 306 is used to detect hemoglobin concentration measurements;
the hematocrit detection module 301 is used to detect red blood cell and platelet counts and morphological parameter measurements;
whole blood CRP measurement module 302 is used to detect C-reactive protein measurements (immuno-transmission turbidimetry);
the correction module 303 is configured to correct the measured whole blood CRP concentration value according to the measured hematocrit value.
When the mode selection unit 1 selects the whole blood CRP single measurement mode, the control unit 2 calls the hematocrit measurement module 301, the whole blood CRP measurement module 302 and the correction module 303 to measure the CRP concentration value; when the mode selection unit 1 selects the CBC blood cell classification measurement mode, the BASO detection module 304, the DIFF detection module 305, the HGB detection module 306 and the hematocrit measurement module 301 are called to perform five classification measurement of CBC blood cells; when the CBC blood cell classification and CRP mode is selected by the mode selection unit 1, the BASO detection module 304, the DIFF detection module 305, the HGB detection module 306, and the hematocrit measurement module 301 are invoked to perform five classification measurements of CBC blood cells, and the hematocrit measurement module 301, the whole blood CRP measurement module 302, and the correction module 303 are invoked to perform CRP concentration value measurements. Here, when the CRP concentration value is measured at this time, the hematocrit measurement module 301 is called without re-measurement, and only the hematocrit value calculated when the hematocrit measurement module 301 performs CBC hematocrit five classification measurement is required to be obtained, and the correction module 303 corrects the measured CRP concentration value according to the obtained hematocrit value.
Among the three measurement modes provided by the blood analyzer, the blood volume required for the test in the whole blood CRP single measurement mode is 15-25 microliters, the blood volume required for the test in the CBC blood cell sorting and CRP modes is 30-40 microliters, and the blood volume required for the test in the CBC blood cell sorting measurement mode is 15-35 microliters. It can be seen that the blood volume required for measuring CRP alone is only about half that for measuring both CBC blood cell classification and CRP simultaneously, reducing blood volume.
The measurement method of the blood analyzer of the present embodiment includes the steps of:
a measurement mode is selected in which any one of a whole blood CRP-alone measurement mode, a CBC blood cell classification and CRP mode, and a CBC blood cell classification measurement mode can be selected.
(1) When the whole blood CRP alone measurement mode was selected:
the control unit 2 calls a hematocrit measuring module 301, a whole blood CRP measuring module 302 and a correcting module 303 to measure;
after receiving the call instruction of the control unit 2, the measurement unit 1 obtains a hematocrit value through the hematocrit measurement module 301, obtains a whole blood CRP concentration value through the whole blood CRP measurement module 302, and then the correction module 303 corrects the whole blood CRP concentration value obtained by the whole blood CRP measurement module 302 according to the hematocrit value obtained by the hematocrit measurement module 301 to obtain a corrected CRP concentration value.
(2) When the CBC blood cell classification measurement mode is selected;
the control unit 2 calls the BASO detection module 304, the DIFF detection module 305, the HGB detection module 306, and the hematocrit measurement module 301 in the measurement unit 1 to perform measurement, so as to obtain a measurement value of the CBC blood cell five classification.
(3) When CBC blood cell classification and CRP mode are selected;
the control unit 2 calls the BASO detection module 304, the DIFF detection module 305, the HGB detection module 306, the hematocrit measurement module 301, the whole blood CRP measurement module 302 and the correction module 303 in the measurement unit 3 to perform measurement;
the measurement unit obtains a CBC blood cell five-class value through the BASO detection module 304, the DIFF detection module 305, the HGB detection module 306, and the hematocrit measurement module 301, obtains a whole blood CRP concentration value through the whole blood CRP measurement module 302, directly calls the hematocrit value already obtained by the hematocrit measurement module 301, and corrects the whole blood CRP concentration value obtained by the whole blood CRP measurement module 302 according to the hematocrit value through the correction module 303 to obtain a corrected CRP concentration value.
Example 3
The blood analyzer in this embodiment has the same measurement mode set as that of embodiment 2, except that the measurement unit 3 includes a white blood cell count and three classification module 307, an HGB detection module 306, a hematocrit measurement module 301, a whole blood CRP measurement module 302, and a correction module 303, as shown in fig. 5. The difference between the present example 3 and the example 2 is that the CBC blood cell classification in the present example measures the CBC blood cell three classification, and the CBC blood cell classification in the example 2 measures the CBC blood cell five classification.
In the control unit 2, when the whole blood CRP-alone measurement mode is selected by the mode selection unit 1, the same as in embodiment 2 is performed. When the mode selection unit 1 selects the CBC blood cell classification measurement mode, the leukocyte count and three-classification module 307, the HGB detection module 306, and the hematocrit measurement module 301 are called to perform CBC blood cell three-classification measurement. When the CBC blood cell classification and CRP mode is selected by the mode selection unit 1, the leukocyte count and three-classification module 307, the HGB detection module 306, and the hematocrit measurement module 301 are called to perform CBC blood cell three-classification measurement, and the hematocrit measurement module 301, the whole blood CRP measurement module 302, and the correction module 303 are called to perform CRP concentration value measurement, at this time, when the CRP concentration value measurement is performed, when the hematocrit measurement module 301 is called, only the hematocrit value that has been obtained by the hematocrit measurement module 301 when CBC blood cell three-classification measurement is performed needs to be obtained, and re-measurement is not needed.
Because there are two kinds of CBC blood cell classification measurement, one is CBC blood cell five classification measurement in embodiment 2, another is CBC blood cell three classification measurement in this embodiment, according to each kind of CBC blood cell classification measurement, the invention can provide the blood analyzer which realizes its function, facilitate the user to choose according to the need.
Example 4：
Based on the above embodiment 2, in this embodiment, the measurement mode set further includes CBC measurement and CRP mode, and when the CBC measurement and CRP mode are used for measurement, only CBC measurement and CRP concentration value measurement are performed, and CBC blood cell classification is not measured.
In this embodiment, as shown in fig. 6, the mode selection unit 1 selects one measurement mode from a measurement mode set, where the measurement mode set includes a whole blood CRP single measurement mode, a CBC blood cell classification and CRP mode, a CBC blood cell classification measurement mode, a CBC measurement and CRP mode;
the measurement unit 3 includes a BASO detection module 304, a DIFF detection module 305, an HGB detection module 306, a hematocrit measurement module 301, a whole blood CRP measurement module 302, and a correction module 303. The BASO detection module 304 is used to detect the white blood cell count and the basophil classification, the DIFF detection module 305 is used to detect the white blood cell four classification, and the HGB detection module 306 is used to detect the hemoglobin concentration. The correcting module 303 corrects the whole blood CRP concentration value obtained by the whole blood CRP measuring module 302 according to the hematocrit value obtained by the hematocrit measuring module 301 to obtain a corrected CRP concentration value.
And the control unit 2 calls each corresponding module in the measurement unit 3 to perform corresponding measurement according to the measurement mode selected in the mode selection unit 1. Specifically, the method comprises the following steps:
when the mode selection unit 1 selects the whole blood CRP single measurement mode, calling the hematocrit measurement module 301, the whole blood CRP measurement module 302 and the correction module 303 to measure the CRP concentration value;
when the mode selection unit 1 selects the CBC blood cell classification measurement mode, the BASO detection module 304, the DIFF detection module 305, the HGB detection module 306 and the hematocrit measurement module 301 are called to perform five classification measurement of CBC blood cells;
when the CBC blood cell classification and CRP mode is selected by the mode selection unit 1, calling the BASO detection module 304, the DIFF detection module 305, the HGB detection module 306, and the hematocrit measurement module 301 to perform five-class measurement of CBC blood cells, and calling the hematocrit measurement module 301, the whole blood CRP measurement module 302, and the correction module 303 to perform CRP concentration value measurement, at this time, calling the hematocrit measurement module 301 only needs to obtain a hematocrit value that has been obtained by the hematocrit measurement module 301 when performing the CBC blood cell five-class measurement;
when the CBC measurement and CRP mode are selected by the mode selection unit 1, the BASO detection module 304, the HGB detection module 306, and the hematocrit measurement module 301 are called to perform CBC measurement, and the hematocrit measurement module 301, the whole blood CRP measurement module 302, and the correction module 303 are called to perform CRP concentration value measurement, at this time, the hematocrit measurement module 301 is called to only need to obtain the hematocrit value that has been obtained by the hematocrit measurement module 301 when CBC measurement is performed.
Of course, CBC measurement and CRP modes may also be added on the basis of embodiment 1 or 3, and the specific implementation manner thereof is the same as above and will not be described again.
In a preferred embodiment, the whole blood CRP measurement module 302 can also determine the dosage of the added hemolytic agent based on the hematocrit value measured by the hematocrit measurement module 301. The larger the hematocrit value is, the more hemolytic agent is required, so that the dosage of hemolytic agent is selected according to the hematocrit value measured in the hematocrit measurement module 301, which can better save reagent and ensure the accuracy of measurement result.
Example 5:
the blood analyzer of the present embodiment is further provided with the following test type automatic selection unit 4, and can realize separate processing of whole blood and serum or plasma.
The blood analyzer in this embodiment further includes a test type automatic selection unit 4 on the basis of embodiment 1, and the measurement unit 3 further includes a serum CRP measurement module 308, and the schematic structural diagram is shown in fig. 7. When the hematocrit value measured by the hematocrit measurement module 301 is smaller than a preset threshold value, the test type automatic selection unit 4 judges that the measured blood sample is serum or plasma, and invokes the serum CRP measurement module 308 to measure the CRP concentration value; otherwise, the measured blood sample is judged to be whole blood, and the whole blood CRP measurement module 302 and the correction module 303 are called to measure the CRP concentration value.
The preset threshold may be set to 0, or a smaller value such as 0.0001, etc., according to the required device. Assuming that the preset threshold is 0, when the hematocrit value calculated by the hematocrit measurement module 301 is 0, the test type automatic selection unit 4 may determine that the measured blood sample is serum or plasma; when the calculated hematocrit value is not 0, the automatic test type selection unit 4 may determine that the blood sample is whole blood, and then select the whole blood CRP measurement module 302 or the serum CRP measurement module 308 for measurement according to the determination result.
When the hematocrit value is 0, the sample to be measured is judged to be serum or plasma, and then the serum CRP measuring module 308 is selected in the measuring unit 3 to measure the sample without adding a hemolytic agent or correcting, so that the serum CRP concentration value can be directly obtained. When the hematocrit value is not 0, the sample is judged to be whole blood, the whole blood CRP measuring module 302 and the correcting module 303 are called to carry out measurement according to the hematocrit value measured by the hematocrit measuring module 301, a hemolytic agent is required to be added at the moment, the measured value before the whole blood CRP concentration is corrected is obtained, and then the corrected whole blood CRP concentration value is obtained after the correction by the correcting module 303. At this time, when the whole blood CRP measuring module 302 adds the hemolytic agent, the amount of hemolytic agent required may be further selected according to the magnitude of the hematocrit value measured by the hematocrit measuring module 301, and if the value is larger, more hemolytic agent is required, and the value is smaller, the less hemolytic agent is required. Therefore, the quantity of the hemolytic agent can be reasonably selected, the measurement precision is ensured, and the reagent is saved.
The hematology analyzer of the scheme can also adopt an impedance method to measure the hematocrit value to determine whether the value of the hematocrit is 0 or not, so that whether the blood sample is serum or whole blood is judged, the most suitable mode is adopted for measurement, the measurement precision is improved, and the reagent dosage is saved. The impedance method comprises a primary dilution module and a secondary dilution module, a small amount of samples are expanded to a proper degree through multiple times of dilution, large errors are possibly caused to appear due to the fact that the sample amount is too small, and the total amount of the samples reaches a certain degree through a secondary dilution mode, so that the detection precision is favorably improved.
In other implementations, the hematology analyzer can further include the following three measurement modes based on the single measurement mode of whole blood CRP as required: one or more selected from CBC blood cell classification and CRP mode, CBC blood cell classification measurement mode, CBC measurement and CRP mode can be combined at will.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (10)
1. A blood analyzer, comprising:
a mode selection unit, which is used for selecting a measurement mode from a measurement mode set, wherein the measurement mode set at least comprises a whole blood CRP single measurement mode;
the measuring unit at least comprises a hematocrit measuring module, a whole blood CRP measuring module and a correcting module; the correction module corrects the whole blood CRP concentration value obtained by the whole blood CRP measurement module according to the hematocrit value obtained by the hematocrit measurement module to obtain a corrected CRP concentration value;
and the control unit calls the hematocrit measuring module, the whole blood CRP measuring module and the correction module to measure the CRP concentration value when the whole blood CRP single measuring mode is selected by the mode selection unit.
2. The blood analyzer of claim 1, wherein the set of measurement modes further comprises one or more of a CBC blood cell classification and CRP mode, a CBC blood cell classification measurement mode, a CBC measurement, and a CRP mode.
3. The blood analyzer of claim 2, wherein the measurement unit further comprises: the device comprises a BASO detection module, a DIFF detection module and an HGB detection module; the BASO detection module is used for detecting white blood cell counting and basophil granulocyte classification, the DIFF detection module is used for detecting four types of white blood cells, and the HGB detection module is used for detecting hemoglobin concentration.
4. The blood analyzer of claim 2, wherein the measurement unit further comprises: a leukocyte counting module, a three-classification module and an HGB detection module.
5. The blood analyzer of claim 3, wherein the control unit further comprises:
when the mode selection unit selects the CBC blood cell classification measurement mode, calling the BASO detection module, the DIFF detection module, the HGB detection module and the hematocrit measurement module to carry out five classification measurement on the CBC blood cells;
when the CBC blood cell classification and CRP mode is selected by the mode selection unit, calling the BASO detection module, the DIFF detection module, the HGB detection module and the hematocrit measurement module to perform five-classification measurement on the CBC blood cells, and calling the hematocrit measurement module, the whole blood CRP measurement module and the correction module to perform CRP concentration value measurement;
when the CBC measurement and the CRP mode are selected by the mode selection unit, the BASO detection module, the HGB detection module and the hematocrit measurement module are called to carry out the CBC measurement, and the hematocrit measurement module, the whole blood CRP measurement module and the correction module are called to carry out the CRP concentration value measurement.
6. The blood analyzer of claim 4, wherein the control unit further comprises:
when the mode selection unit selects the CBC blood cell classification measurement mode, calling the white blood cell counting and three classification modules thereof, the HGB detection module and the hematocrit measurement module to carry out three classification measurements of the CBC blood cells;
and when the CBC blood cell classification and CRP mode is selected by the mode selection unit, calling the white blood cell counting and three classification modules thereof, the HGB detection module and the hematocrit measurement module to carry out three-classification measurement on the CBC blood cells, and calling the hematocrit measurement module, the whole blood CRP measurement module and the correction module to carry out CRP concentration value measurement.
7. The hematology analyzer of any one of claims 1-6, wherein the whole blood CRP measurement module further determines the dosage of the added hemolytic agent based on the hematocrit value measured by the hematocrit measurement module.
8. The hematology analyzer of claim 7, further comprising a test type automatic selection unit, the measurement unit further comprising a serum CRP measurement module;
the automatic test type selection unit judges whether the measured blood sample is serum or plasma when the hematocrit value measured by the hematocrit measurement module is smaller than a preset threshold value, and calls the serum CRP measurement module to measure the CRP concentration value; otherwise, the measured blood sample is judged to be whole blood, and the whole blood CRP measuring module and the correction module are called to measure the CRP concentration value.
9. The blood analyzer of any of claims 1-6, wherein the hematocrit measurement module is an impedance measurement module.
10. The measurement device of claim 9, wherein the impedance measurement module comprises a primary filling dilution sub-module, a secondary filling dilution sub-module, a blending sub-module, an impedance method red blood cell measurement sub-module, and a hematocrit calculation sub-module.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410318293.8A CN105334243A (en) | 2014-07-04 | 2014-07-04 | Blood analyzer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410318293.8A CN105334243A (en) | 2014-07-04 | 2014-07-04 | Blood analyzer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105334243A true CN105334243A (en) | 2016-02-17 |
Family
ID=55284896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410318293.8A Pending CN105334243A (en) | 2014-07-04 | 2014-07-04 | Blood analyzer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105334243A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107796809A (en) * | 2017-10-31 | 2018-03-13 | 三诺生物传感股份有限公司 | A kind of method and its kit and device for the detection of finger tip blood wet method |
| CN108732135A (en) * | 2017-11-20 | 2018-11-02 | 重庆中元汇吉生物技术有限公司 | A kind of blood cell and analysis of protein device |
| CN108732338A (en) * | 2017-04-17 | 2018-11-02 | 深圳市帝迈生物技术有限公司 | A kind of classification of compatible leucocyte five and leucocyte three divide the cellanalyzer and test method of group |
| CN109211737A (en) * | 2017-06-30 | 2019-01-15 | 深圳迈瑞生物医疗电子股份有限公司 | Sample testing apparatus, sample analyser and sample testing method |
| CN110501504A (en) * | 2018-05-16 | 2019-11-26 | 深圳市理邦精密仪器股份有限公司 | Blood content detection method and system |
| CN112305245A (en) * | 2019-07-30 | 2021-02-02 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis method and sample analysis system |
| CN112305246A (en) * | 2019-07-30 | 2021-02-02 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis method and sample analysis system |
| CN112305244A (en) * | 2019-07-30 | 2021-02-02 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis method, data management device, computer device, and storage medium |
| CN112798799A (en) * | 2019-11-13 | 2021-05-14 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis system and sample testing method |
| CN113049801A (en) * | 2019-12-28 | 2021-06-29 | 深圳市帝迈生物技术有限公司 | Immunoassay analyzer |
| CN113049800A (en) * | 2019-12-28 | 2021-06-29 | 深圳市帝迈生物技术有限公司 | Immunoassay analyzer, detection method thereof and computer readable storage medium |
| CN115248180A (en) * | 2021-04-26 | 2022-10-28 | 帝迈(苏州)生物技术有限公司 | POCT blood cell analyzer and method of using the same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6106778A (en) * | 1997-09-27 | 2000-08-22 | Horiba, Ltd. | Blood cell count/immunoassay apparatus using whole blood |
| CN101680876A (en) * | 2007-03-22 | 2010-03-24 | 商诊疗有限公司 | Whole blood assay |
| US8101065B2 (en) * | 2009-12-30 | 2012-01-24 | Lifescan, Inc. | Systems, devices, and methods for improving accuracy of biosensors using fill time |
| CN103278439A (en) * | 2007-02-01 | 2013-09-04 | 希森美康株式会社 | Sample analyzer and control system thereof |
-
2014
- 2014-07-04 CN CN201410318293.8A patent/CN105334243A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6106778A (en) * | 1997-09-27 | 2000-08-22 | Horiba, Ltd. | Blood cell count/immunoassay apparatus using whole blood |
| CN103278439A (en) * | 2007-02-01 | 2013-09-04 | 希森美康株式会社 | Sample analyzer and control system thereof |
| CN101680876A (en) * | 2007-03-22 | 2010-03-24 | 商诊疗有限公司 | Whole blood assay |
| US8101065B2 (en) * | 2009-12-30 | 2012-01-24 | Lifescan, Inc. | Systems, devices, and methods for improving accuracy of biosensors using fill time |
Non-Patent Citations (3)
| Title |
|---|
| HORIBA ABX: "《ABX Micros CRP 200 Technical manual》", 27 September 2009 * |
| 甄萍 等: "《全血C_反应蛋白快速检测的应用》", 《临床血液学杂志》 * |
| 黄宇烽，李克: "《现代临床检验诊断手册》", 31 May 2006, 第二军医大学出版社 * |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108732338A (en) * | 2017-04-17 | 2018-11-02 | 深圳市帝迈生物技术有限公司 | A kind of classification of compatible leucocyte five and leucocyte three divide the cellanalyzer and test method of group |
| CN109211737A (en) * | 2017-06-30 | 2019-01-15 | 深圳迈瑞生物医疗电子股份有限公司 | Sample testing apparatus, sample analyser and sample testing method |
| CN107796809A (en) * | 2017-10-31 | 2018-03-13 | 三诺生物传感股份有限公司 | A kind of method and its kit and device for the detection of finger tip blood wet method |
| CN108732135A (en) * | 2017-11-20 | 2018-11-02 | 重庆中元汇吉生物技术有限公司 | A kind of blood cell and analysis of protein device |
| CN110501504B (en) * | 2018-05-16 | 2024-03-12 | 深圳市理邦精密仪器股份有限公司 | Blood content detection method and system |
| CN110501504A (en) * | 2018-05-16 | 2019-11-26 | 深圳市理邦精密仪器股份有限公司 | Blood content detection method and system |
| CN112305245A (en) * | 2019-07-30 | 2021-02-02 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis method and sample analysis system |
| CN112305246A (en) * | 2019-07-30 | 2021-02-02 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis method and sample analysis system |
| CN112305244A (en) * | 2019-07-30 | 2021-02-02 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis method, data management device, computer device, and storage medium |
| CN112305246B (en) * | 2019-07-30 | 2025-06-13 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis method and sample analysis system |
| CN112305245B (en) * | 2019-07-30 | 2024-04-19 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis method and sample analysis system |
| CN112798799A (en) * | 2019-11-13 | 2021-05-14 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis system and sample testing method |
| CN112798799B (en) * | 2019-11-13 | 2024-01-16 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis system and sample testing method |
| CN113049800A (en) * | 2019-12-28 | 2021-06-29 | 深圳市帝迈生物技术有限公司 | Immunoassay analyzer, detection method thereof and computer readable storage medium |
| CN113049800B (en) * | 2019-12-28 | 2024-05-28 | 深圳市帝迈生物技术有限公司 | Immunoassay analyzer, detection method thereof and computer readable storage medium |
| CN113049801B (en) * | 2019-12-28 | 2024-07-05 | 深圳市帝迈生物技术有限公司 | Immunoassay analyzer |
| CN113049801A (en) * | 2019-12-28 | 2021-06-29 | 深圳市帝迈生物技术有限公司 | Immunoassay analyzer |
| CN115248180A (en) * | 2021-04-26 | 2022-10-28 | 帝迈(苏州)生物技术有限公司 | POCT blood cell analyzer and method of using the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105334243A (en) | Blood analyzer | |
| US10222320B2 (en) | Identifying and enumerating early granulated cells (EGCs) | |
| US11125687B2 (en) | Method and device for identifying fragmented red blood cells, blood cell analyzer and analysis method | |
| CN109270281A (en) | Improve the method and apparatus of leukocyte differential count result accuracy and count results repeatability | |
| CN111912978B (en) | Method and device for classifying and counting white blood cells and blood analyzer | |
| CN104949944A (en) | Blood analyzer | |
| CN106018773A (en) | Disposable blood cell counting and analyzing integrated reagent sensing unit and novel blood analyzer | |
| ITUD20060177A1 (en) | INTEGRATED EQUIPMENT AND METHOD FOR DETECTION OF INFLAMMATORY STATES PRESENT IN A WHOLE BLOOD SAMPLE | |
| US20220113238A1 (en) | Method for classifying and counting white blood cells, hematology analyzer, and computer readable storage medium | |
| CN105785061B (en) | The bearing calibration of sample-adding amount and system | |
| CN113252537B (en) | Sample analyzer and counting abnormity detection method thereof | |
| CN215525833U (en) | Blood analyzer | |
| WO2021147179A1 (en) | Blood particle detection method and blood analyzer thereof | |
| EP3410114A1 (en) | Urine analyzer and urinanalysis method | |
| EP4010682B1 (en) | Detecting and reporting subpopulations of neutrophils | |
| Dewi et al. | Analysis of Blood Sample Lysis Rate on Hemoglobin Examination Results Using Rayto RT. 7600 Auto Hematology Analyzer | |
| CN113466473A (en) | Sample analyzer and sample analysis method and system | |
| CN111051887A (en) | Analysis device and analysis method | |
| JP2005077148A (en) | Blood examination method and device | |
| Butch et al. | A multicenter evaluation of the Iris iQ200 automated urine microscopy analyzer body fluids module and comparison with hemacytometer cell counts | |
| JPH04151541A (en) | cell analyzer | |
| CN114618853A (en) | Cleaning method of sample analyzer and sample analyzer | |
| CN118067589A (en) | Method, device, terminal equipment and medium for classifying white blood cells of animal blood sample | |
| CN120233075A (en) | Blood cell analyzer and counting method thereof | |
| WO2022116112A1 (en) | Sample analysis system and method, sample image analysis system and blood analyzer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160217 |